Abbott Laboratories
General ticker "ABT" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $193.5B (TTM average)
Abbott Laboratories does not follow the US Stock Market performance with the rate: -26.9%.
Estimated limits based on current volatility of 1.1%: low 103.58$, high 105.88$
Factors to consider:
- Earnings expected soon, date: 2026-10-21 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-07-15, amount 0.63$ (Y2.40%)
- Total employees count: 115000 (+0.9%) as of 2025
- US accounted for 0.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Acquisition/divestiture risks, Cybersecurity threats, Commercialization failure, Regulatory and compliance
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [106.83$, 148.65$]
- 2026-12-31 to 2027-12-31 estimated range: [112.82$, 155.79$]
Financial Metrics affecting the ABT estimates:
- Negative: with PPE of 24.3 at the end of fiscal year the price was high
- Positive: 15.80 < Operating profit margin, % of 18.17
- Positive: 2.37 < Operating cash flow per share per price, % of 4.38
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 7.00
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Positive: Inventory ratio change, % of -0.10 <= 0
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
Short-term ABT quotes
Long-term ABT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $40,109.00MM | $41,950.00MM | $44,328.00MM |
| Operating Expenses | $33,631.00MM | $35,125.00MM | $36,275.00MM |
| Operating Income | $6,478.00MM | $6,825.00MM | $8,053.00MM |
| Non-Operating Income | $186.00MM | $188.00MM | $413.00MM |
| Interest Expense | $637.00MM | $559.00MM | $493.00MM |
| R&D Expense | $2,741.00MM | $2,844.00MM | $2,942.00MM |
| Income(Loss) | $6,664.00MM | $7,013.00MM | $8,466.00MM |
| Taxes | $941.00MM | $-6,389.00MM | $1,942.00MM |
| Net Income(Loss)* | $5,723.00MM | $13,402.00MM | $6,524.00MM |
| Stockholders Equity | $38,603.00MM | $47,664.00MM | $52,130.00MM |
| Inventory | $6,570.00MM | $6,194.00MM | $6,488.00MM |
| Assets | $73,214.00MM | $81,414.00MM | $86,713.00MM |
| Operating Cash Flow | $7,261.00MM | $8,558.00MM | $9,566.00MM |
| Capital expenditure | $2,202.00MM | $2,207.00MM | $2,171.00MM |
| Investing Cash Flow | $-3,133.00MM | $-2,338.00MM | $-2,422.00MM |
| Financing Cash Flow | $-7,091.00MM | $-5,404.00MM | $-6,309.00MM |
| Earnings Per Share** | $3.30 | $7.74 | $3.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.